Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00682929 · ClinicalTrials.gov registry record · Phase 1
Cannabis for Spasticity in Multiple Sclerosis
A Phase 1 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00682929: Clinical Trial Phase 1 study, sponsored by University of California, Davis.
NCT00682929 is a Phase 1 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00682929, a Phase 1 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if the use of inhaled cannabis (marijuana) and oral cannabinoid (dronabinol, Marinol or THC, which is an active ingredient of marijuana) is safe and effective in reducing the symptoms of spasticity and tremor in patients with secondary-progressive or primary progressive multiple sclerosis.
Primary Outcome
A modified servo-controlled torque motor system (Lido WorkSet II) was designed for this study to analyze the resistance to passive movement of the knee. It determines the amount of torque required to move the knee joint (without voluntary resistance) at high velocities (up to 200 degrees per second) and at slow velocities (as low as 10 degrees per second). The slow displacement torque is a measure of the passive resistance to movement (from the connective tissue and the non-contracting muscle) a
Interventions
- DRUG Oral Placebo
- DRUG Inhaled placebo
- DRUG Oral THC
- DRUG Inhaled Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2004-04-14 |
| Est. Completion | 2011-08-17 |
| Phase | Phase 1 |
Why NCT00682929 stopped before completion
NCT00682929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 4 interventions - of which Oral Placebo is the first listed.
NCT00682929 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00682929 about?
NCT00682929 is a clinical study titled "Cannabis for Spasticity in Multiple Sclerosis". The purpose of this study is to learn if the use of inhaled cannabis (marijuana) and oral cannabinoid (dronabinol, Marinol or THC, which is an active ingredient of marijuana) is safe and effective in reducing the symptoms of spasticity and tremor in patients with secondary-progressive or primary pro...
What is the current status of trial NCT00682929?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2004-04-14. Estimated completion is 2011-08-17.
What interventions are being tested in trial NCT00682929?
The interventions under investigation include: Oral Placebo (DRUG), Inhaled placebo (DRUG), Oral THC (DRUG), Inhaled Cannabis (DRUG).
Who is sponsoring clinical trial NCT00682929?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00682929's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI